Other
Short-term debt and current portion of long-term debt
Bristol-Myers Squibb Short-term debt and current portion of long-term debt increased by 10.5% to $2.26B in Q4 2025 compared to the prior quarter. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryLeverage
SignalLower is better
VolatilityModerate
First reportedQ4 2025
Last reportedQ1 2026
How to read this metric
A significant increase may signal higher refinancing risk or a shift in capital structure, while a decrease indicates debt reduction or successful long-term refinancing.
Detailed definition
This represents the portion of total debt obligations, including bank loans, commercial paper, and the current portion o...
Peer comparison
Standard debt metric; peers report this as current portion of long-term debt or short-term borrowings.
Metric ID:
other_debt_currentHistorical Data
2 periods
| Q4 '24 | Q4 '25 | |
|---|---|---|
| Value | $2.05B | $2.26B |
| QoQ Change | — | +10.5% |
| YoY Change | — | +10.5% |
Range$2.05B – $2.26B
Avg YoY Growth+10.5%
Median YoY Growth+10.5%
Short-term debt and current portion of long-term debt at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's short-term debt and current portion of long-term debt?
- Bristol-Myers Squibb (BMY) reported short-term debt and current portion of long-term debt of $2.26B in Q4 2025.
- What does short-term debt and current portion of long-term debt mean?
- The amount of debt the company must repay within the next year.